mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0099 |
0.8 |
mRNA |
etoposide |
CTRPv2 |
pan-cancer |
AAC |
-0.0086 |
0.8 |
mRNA |
tandutinib |
CTRPv2 |
pan-cancer |
AAC |
-0.01 |
0.8 |
mRNA |
Cisplatin |
GDSC1000 |
pan-cancer |
AAC |
-0.01 |
0.8 |
mRNA |
betulinic acid |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.8 |
mRNA |
BRD-K55473186 |
CTRPv2 |
pan-cancer |
AAC |
-0.013 |
0.8 |
mRNA |
quizartinib |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.8 |
mRNA |
QL-X-138 |
GDSC1000 |
pan-cancer |
AAC |
-0.0091 |
0.8 |
mRNA |
BRD9876:MK-1775 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.033 |
0.8 |
mRNA |
tipifarnib |
CTRPv2 |
pan-cancer |
AAC |
0.0087 |
0.8 |